Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Discovery of new anti-tuberculosis (TB) drugs is a time-consuming process due to the slow-growing nature of Mycobacterium tuberculosis (Mtb). A requirement of biosafety level 3 (BSL-3) facility for performing research associated with Mtb is another limitation for the development of TB drug discovery. In our screening of BSL-1 Mycobacterium spp. against a battery of TB drugs, M. smegmatis (ATCC607) exhibits good agreement with its drug susceptibility against the TB drugs under a low-nutrient culture medium (0.5% Tween 80 in Middlebrook 7H9 broth). M. smegmatis (ATCC607) enters its dormant form in 14 days under a nutrient-deficient condition (a PBS buffer), and shows resistance to a majority of TB drugs, but shows susceptibility to amikacin, capreomycin, ethambutol, and rifampicin (with high concentrations) whose activities against non-replicating (or dormant) Mtb were previously validated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structural absorption by barbule microstructures of super black bird of paradise feathers
McCoy, D. E., Feo, T., Harvey, T. A., & Prum, R. O. (2018) · Nature Communications · doi:10.1038/s41467-017-02088-w · Cited by 7,424
Collins, L., & Franzblau, S. G. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.5.1004 · Cited by 1,599
Mycobacterium tuberculosis Pathogenesis and Molecular Determinants of Virulence
Smith, I. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.3.463-496.2003 · Cited by 1,154
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141 · cited 1×
“demonstrated that non-replicating Mtb cells show resistance to a majority of TB drugs [2, 52].”
BackgroundFranzblau, S. G., Witzig, R. S., McLaughlin, J. C., Torres, P., Madico, G., Hernandez, A., Degnan, M. T., Cook, M. B., Quenzer, V. K., Ferguson, R. M., et al. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.2.362-366.1998 · Cited by 964
de Steenwinkel, J. E. M., de Knegt, G. J., ten Kate, M. T., van Belkum, A., Verbrugh, H. A., Kremer, K., van Soolingen, D., & Bakker-Woudenberg, I. A. J. M. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq374 · Cited by 164 · cited 1×
“smegmatis in a time-dependent manner: 15 days treatment of EMB showed no countable colony [60].”
Background
Cited by
Kumar, N., Sharma, S., & Kaushal, P. S. (2024) · Nature Communications · doi:10.1038/s41467-024-44879-y · Cited by 20
Zarin, S., Shariq, M., Rastogi, N., Ahuja, Y., Manjunath, P., Alam, A., Hasnain, S. E., & Ehtesham, N. Z. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05200-8 · Cited by 13
de Munnik, M., Calvopiña, K., Rabe, P., & Schofield, C. J. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00126-25 · Cited by 1
Metadata
- Authors
- Lelovic, N., Mitachi, K., Yang, J., Lemieux, M. R., Ji, Y., & Kurosu, M.
- Venue
- The Journal of Antibiotics
- Published
- 2020-05-29
- Volume
- 73
- Issue
- 11
- Pages
- 780-789
- ISSN
- 0021-8820 (ISSN-L)
- 1881-1469
- OpenAlex
- W3032759588
- Cited by
- 80
- References
- 6
- FWCI
- 1.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. https://app.cochat.ai/papers/10.1038/s41429-020-0320-7
- The paper
- Lelovic, N., Mitachi, K., Yang, J., Lemieux, M. R., Ji, Y., & Kurosu, M. (2020). Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. The Journal of Antibiotics. https://doi.org/10.1038/s41429-020-0320-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.